FUNDC1 and hepatocellular carcinoma: FUNDC1 overexpression correlates with poor prognosis and therapeutic resistance in various human malignancies, such as cervical cancer, laryngeal cancer, hepatocellular carcinoma, pancreatic cancer, and urothelial cancer21-25.